Tag: PAA
PharmAust receives tablets for motor neurone disease clinical trial
PharmAust (ASX: PAA) is on track to start a clinical trial of its monepantel (MPL) drug in motor neurone disease (MND) this month following the delivery of tablets to its trial site in Melbourne.
T...
PharmAust expands phase 2 canine B cell lymphoma MPL trial to US
PharmAust’s (ASX: PAA) phase two trial evaluating its monepantel (MPL) drug in canines with B cell lymphoma has now expanded to the United States.
The expansion comes after an agreement with Pathwa...
PharmAust latest report gives green light for continuing trials
PharmAust (ASX: PAA) has announced the company is adequately funded to continue its current activities after releasing its March quarter (Q3 FY22) report this week.
The Perth-based clinical stage b...
PharmAust receives $708,000 in R&D tax refund, strengthens financial position for upcoming clinical trials
Clinical stage biotechnology company PharmAust (ASX: PAA) has received a $708,000 research and development (R&D) tax refund for work undertaken by its wholly-owned subsidiaries Epichem and Pitney ...
PharmAust moves closer to clinical trial of MPL in motor neuron disease
Clinical-stage biotech PharmAust (ASX: PAA) is closer to starting a phase 1 clinical trial evaluating its monepantel (MPL) drug in motor neuron disease (MND) after receiving its first instalment of a ...
PharmAust commences manufacture of monepantel tablets
Australian clinical-stage biotechnology company PharmAust (ASX: PAA) has commenced the manufacture of monepantel tablets to enable clinical trials into motor neurone disease and coronavirus.
The co...
PharmAust demonstrates MPL can destroy leukaemia virus in pre-clinical research
Biotech PharmAust (ASX: PAA) has demonstrated its lead drug monepantel (MPL) can kill the leukaemia virus, while also having an anti-cancer effect, during pre-clinical research.
The Walter and Eliz...
PharmAust engages UK research company for clinical trials of monepantel on COVID-19 patients
Clinical-stage biotechnology company PharmAust (ASX: PAA) has engaged UK-based Ergomed Clinical Research to commence clinical trials into the anti-viral effects of lead drug monepantel (MPL) in patien...
PharmAust lodges patent application for the use of monepantel in viral diseases
Clinical-stage biotechnology company PharmAust (ASX: PAA) has lodged a patent application for the use of its lead drug monepantel in a range of viral diseases.
The PCT (Patent Co-operative Treaty) ...
PharmAust collaborates with Walter and Eliza Hall Institute to test antiviral potential of MPL in HTLV-1
PharmAust (ASX: PAA) will evaluate the impact of its monepantel (MPL) drug on the human t-lymphotropic virus-1 (HTLV-1) under a new research agreement with Melbourne’s Walter and Eliza Hall Institute....
Independent tests show PharmAust’s monepantel drug will retain long-term shelf-life and product stability
Clinical-stage biotechnology company PharmAust (ASX: PAA) has reported positive results from ongoing product stability and shelf-life testing of its lead anti-cancer drug candidate monepantel in table...
PharmAust’s monepantel trials to move to phase III after significant anti-cancer results
PharmAust Limited’s (ASX: PAA) clinical trials testing anti-cancer drug monepantel in canine lymphoma has successfully achieved phase two primary endpoints with administering veterinarians now wanting...
PharmAust secures ethics approval, prepares for clinical trial of MPL in patients with motor neurone disease
After securing ethics approval, PharmAust (ASX: PAA) is gearing up to begin a phase I clinical trial in the December quarter, which will assess its monepantel drug in patients with motor neurone disea...
PharmAust secures new lead researcher for phase IIb monepantel trial on canine lymphoma
Clinical stage oncology company PharmAust (ASX: PAA) has appointed Dr Kim Agnew as the new principal investigator for its phase IIb veterinary clinical trial testing anti-cancer drug monepantel in pet...
PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19
Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma.
During the March quarter, PharmAust...
PharmAust’s phase IIb monepantel trial identifies therapeutic window for treatment of canine lymphoma
An interim analysis of a phase IIb trial conducted by clinical-stage oncology company PharmAust (ASX: PAA) has provided supportive evidence of a therapeutic window for lead drug candidate monepantel t...
PharmAust secures $750,000 R&D refund from ATO
Clinical-stage oncology company PharmAust (ASX: PAA) has received a hefty rebate from the Australian Tax Office under the national research and development tax incentive scheme for the work of its who...
PharmAust’s MPL and MPLS drug candidates again indicate antiviral activity in SARS-CoV2
Further pre-clinical testing of PharmAust’s (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured cell infection models of SARS-CoV2 ...
PharmAust reveals early results from phase IIb canine lymphoma trial
PharmAust (ASX: PAA) has completed assessment of the first five dogs in a phase IIb trial of its anti-cancer drug monepantel on treatment-naïve B cell lymphoma in canines, revealing only minimal side ...
PharmAust subsidiary Epichem to advance ‘world first’ waste-to-fuel conversion technology
PharmAust’s (ASX: PAA) subsidiary Epichem has inked a licencing deal that will see it research, develop and promote a disruptive flow reactor technology that converts waste to fuel.
Thermaquatica f...
PharmAust calls for more dogs for anti-cancer canine drug trial
Biotech company PharmAust (ASX: PAA) has officially begun recruitment for the phase IIb trial of its lead anti-cancer drug monepantel (MPL) on canine lymphoma and has put a call out for more dogs to p...
